Moderna, largest biotech to go public, fails to impress in market debut

Moderna Inc’s MRNA.O shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.